Den 7-9 mai 2025 er Almirall Diamant-sponsor under NCDV, Nordic Congress of Dermatology and Venereology, i Helsinki
Almirall er Diamant-sponsor under NCDV, den 7-9 mai 2025 i Helsinki
-
-
Almirall’s Ilumetri® (tildrakizumab) demonstrates high rates of skin clearance and sustained wellbeing restoration in Adults with Moderate-to-Severe Plaque Psoriasis to general population levels for up to one year (1)
• Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing
• This first-of-its-kind study underscores the psychosocial burden of psoriasis and its deep im -
EBGLYSS® (lebrikizumab) er ny førsteplasserte interleukin-hemmere for alvorlig atopisk dermatitt hos voksne og ungdom på TNF BIO 2406b fra 1. mai 2024 (1,2)
Norge er det første landet i Norden hvor lebrikizumab blir tilgjengelig som reseptpliktig medisin. Lebrikizumab (EBGLYSS) er rangert som nummer en av interleukin-hemmerne for alvorlig atopisk dermatitt (AD) hos voksne og ungdom på TNF-BIO 2406b fra 1. mai 20241,2.
OSLO, Norge. 28. mai 2024 – Almirall, et globalt legemiddelfirma med fokus på medisinsk dermatologi kunngjorde i dag lansering -
Almirall initiates first phase I clinical study of ALM223, an interleukin 2 mutant fusion protein for autoimmune diseases
• The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223
• ALM223 has the potential to rebalance the immune system in several autoimmune diseases (1,2)
BARCELONA, Spain. 21st December, 2023 – Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study ev -
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
• The multi-target research and development partnership will focus on severe skin diseases
• The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
• In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial milestones as well as ti -
Almirall får EU-godkjennelse av EBGLYSS ® (lebrikizumab) for moderat til alvorlig atopisk dermatitt.
Lebrikizumab er et monoklonalt antistoff, som binder seg til IL-13 med høy affinitet og selektivt hemmer nedstrøms signalisering (1, 2, 3, 4). Lebrikizumab har vist tidlig klinisk effekt og vedvarende respons i opp til 2 år i både monoterapi og i kombinasjon med topikale kortikosteroider (5, 6, 7, 8). Tyskland er det første landet hvor lebrikizumab blir tilgjengelig som reseptpliktig medisin.
A -
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases
BARCELONA, Spain and VANCOUVER, (WA), USA. November 14th, 2023 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today
